Combination CAR-T Cell Therapy Targeting Hematological Malignancies

NCT03125577 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

B-cell Malignancies

Interventions

BIOLOGICAL: 4SCAR19 and 4SCAR22
BIOLOGICAL: 4SCAR19 and 4SCAR38
BIOLOGICAL: 4SCAR19 and 4SCAR20
BIOLOGICAL: 4SCAR19 and 4SCAR123
BIOLOGICAL: 4SCAR19 and 4SCAR70
BIOLOGICAL: 4SCAR19 and 4SCAR30

Sponsor

Shenzhen Geno-Immune Medical Institute